154 related articles for article (PubMed ID: 33050332)
21. Comparison of Radiomics Analyses Based on Different Magnetic Resonance Imaging Sequences in Grading and Molecular Genomic Typing of Glioma.
Huang WY; Wen LH; Wu G; Hu MZ; Zhang CC; Chen F; Zhao JN
J Comput Assist Tomogr; 2021 Jan-Feb 01; 45(1):110-120. PubMed ID: 33475317
[TBL] [Abstract][Full Text] [Related]
22. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.
Chen R; Ravindra VM; Cohen AL; Jensen RL; Salzman KL; Prescot AP; Colman H
Neurosurg Focus; 2015 Mar; 38(3):E2. PubMed ID: 25727224
[TBL] [Abstract][Full Text] [Related]
23. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.
Mur P; Rodríguez de Lope Á; Díaz-Crespo FJ; Hernández-Iglesias T; Ribalta T; Fiaño C; García JF; Rey JA; Mollejo M; Meléndez B
J Neurooncol; 2015 May; 122(3):441-50. PubMed ID: 25682093
[TBL] [Abstract][Full Text] [Related]
24. miRNA array screening reveals cooperative MGMT-regulation between miR-181d-5p and miR-409-3p in glioblastoma.
Khalil S; Fabbri E; Santangelo A; Bezzerri V; Cantù C; Di Gennaro G; Finotti A; Ghimenton C; Eccher A; Dechecchi M; Scarpa A; Hirshman B; Chen C; Ferracin M; Negrini M; Gambari R; Cabrini G
Oncotarget; 2016 May; 7(19):28195-206. PubMed ID: 27057640
[TBL] [Abstract][Full Text] [Related]
25. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.
Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A
J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773
[TBL] [Abstract][Full Text] [Related]
26. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
27. Clinical and Molecular Recursive Partitioning Analysis of High-grade Glioma Treated With IMRT.
Sutera P; Kalash R; Flickinger J; Engh J; Heron DE
Am J Clin Oncol; 2019 Jan; 42(1):27-35. PubMed ID: 29912004
[TBL] [Abstract][Full Text] [Related]
28. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
[TBL] [Abstract][Full Text] [Related]
29. MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel.
Grossman R; Burger P; Soudry E; Tyler B; Chaichana KL; Weingart J; Olivi A; Gallia GL; Sidransky D; Quiñones-Hinojosa A; Ye X; Brem H
J Clin Neurosci; 2015 Dec; 22(12):1938-42. PubMed ID: 26249244
[TBL] [Abstract][Full Text] [Related]
30. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
[TBL] [Abstract][Full Text] [Related]
31. Correlation of the quantitative level of MGMT promoter methylation and overall survival in primary diagnosed glioblastomas using the quantitative MethyQESD method.
von Rosenstiel C; Wiestler B; Haller B; Schmidt-Graf F; Gempt J; Bettstetter M; Rihani L; Wu W; Meyer B; Schlegel J; Liesche-Starnecker F
J Clin Pathol; 2020 Feb; 73(2):112-115. PubMed ID: 31422371
[TBL] [Abstract][Full Text] [Related]
32. MGMT Promoter Methylation and IDH1 Mutations Do Not Affect [
Cimini A; Chiaravalloti A; Ricci M; Villani V; Vanni G; Schillaci O
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066633
[TBL] [Abstract][Full Text] [Related]
33. An Innovative Fluorescent Semi-quantitative Methylation-specific PCR Method for the Determination of MGMT Promoter Methylation is Reflecting Intra-tumor Heterogeneity.
Nguyen A; Legrain M; Noel G; Coca A; Meyer Ea N; Schott R; Lasthaus C; Chenard MP; Gaub MP; Lessinger JM; Guenot D; Entz-Werle N
Curr Cancer Drug Targets; 2015; 15(7):624-40. PubMed ID: 26118907
[TBL] [Abstract][Full Text] [Related]
34. Epilysin is overexpressed in glioblastoma and related to clinical outcome of patients.
Wang X; Zhang K; Chen X; Zhao C; Sun Z
Med Oncol; 2015 Jan; 32(1):363. PubMed ID: 25429835
[TBL] [Abstract][Full Text] [Related]
35. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
[TBL] [Abstract][Full Text] [Related]
36. Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors.
Bady P; Delorenzi M; Hegi ME
J Mol Diagn; 2016 May; 18(3):350-361. PubMed ID: 26927331
[TBL] [Abstract][Full Text] [Related]
37. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
[TBL] [Abstract][Full Text] [Related]
38. HDAC4, a prognostic and chromosomal instability marker, refines the predictive value of MGMT promoter methylation.
Cheng W; Li M; Cai J; Wang K; Zhang C; Bao Z; Liu Y; Wu A
J Neurooncol; 2015 Apr; 122(2):303-12. PubMed ID: 25557107
[TBL] [Abstract][Full Text] [Related]
39. Association between glioblastoma cell-derived vessels and poor prognosis of the patients.
Mei X; Chen YS; Zhang QP; Chen FR; Xi SY; Long YK; Zhang J; Cai HP; Ke C; Wang J; Chen ZP
Cancer Commun (Lond); 2020 May; 40(5):211-221. PubMed ID: 32359215
[TBL] [Abstract][Full Text] [Related]
40. Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas.
Li MY; Yang P; Liu YW; Zhang CB; Wang KY; Wang YY; Yao K; Zhang W; Qiu XG; Li WB; Peng XX; Wang YZ; Jiang T
Sci Rep; 2016 Feb; 6():21141. PubMed ID: 26879272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]